Mercado Ásia-Pacífico de diagnóstico de cancro da tiroide – Tendências e previsões do setor para 2030

Pedido de resumo Pedido de TOC Fale com Analista Fale com o analista  Comprar agora Comprar agora Consulte antes Comprar Consulte antes Relatório de amostra grátis Relatório de amostra grátis

Mercado Ásia-Pacífico de diagnóstico de cancro da tiroide – Tendências e previsões do setor para 2030

  • Medical Devices
  • Publish Reports
  • Feb 2023
  • Asia-Pacific
  • 350 Páginas
  • Número de tabelas: 248
  • Número de figuras: 47

Mercado de diagnóstico de cancro da tiroide Ásia-Pacífico, por tipo de produto (instrumentos, consumíveis e acessórios), tipo de teste (teste de imagem, biópsia, análise ao sangue, outros), tipo de cancro (carcinoma papilar, carcinoma folicular, outros), estádios (estádio I, Estádio II, Estádio III, Estádio IV), grupo etário (abaixo dos 21, 21-29, 30-65, 65 e acima), utilizador final (hospital, laboratórios associados, laboratórios de diagnóstico independentes , centros de diagnóstico por imagem, institutos de investigação do cancro e Outros), Canal de Distribuição (Concurso Directo, Vendas a Retalho) - Tendências do Sector e Previsão para 2030.

Mercado Ásia-Pacífico de diagnóstico de cancro da tiroide

Análise e insights do mercado de diagnóstico de cancro da tiroide da Ásia-Pacífico

O aumento da consciencialização sobre o cancro da tiroide aumentou a procura do mercado. O aumento dos gastos em saúde para melhores serviços de saúde também contribui para o crescimento do mercado. Os principais players do mercado concentram-se em diversos lançamentos e aprovações de serviços durante este período crucial. Além disso, o aumento de processos e técnicas de diagnóstico melhorados também contribui para a crescente procura de testes de diagnóstico do cancro da tiróide.

Mercado Ásia-Pacífico de diagnóstico de cancro da tiroide

Mercado Ásia-Pacífico de diagnóstico de cancro da tiroide

O mercado de diagnóstico de cancro da tiroide da Ásia-Pacífico deverá crescer no período de previsão de 2023 a 2030. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 5,0% no período de previsão de 2023 a 2030 e prevê-se que atinja os 1.572,00 milhões de USD até 2030.

Métrica de reporte

Detalhes

Período de previsão

2023 a 2030

Ano base

2022

Ano histórico

2021 (personalizável para 2020-2015)

Unidades Quantitativas

Receita em milhões de dólares

Segmentos cobertos

Por tipo de produto (instrumentos, consumíveis e acessórios), tipo de teste (teste de imagem, biópsia, análise ao sangue, outros), tipo de cancro (carcinoma papilar, carcinoma folicular, outros), estádios (estadio I, estádio II, estádio III, estádio IV ), faixa etária (abaixo dos 21, 21-29, 30-65, 65 e acima), utilizador final (hospital, laboratórios associados, laboratórios de diagnóstico independentes, centros de diagnóstico por imagem, institutos de investigação do cancro e outros), canal de distribuição (concurso direto , Vendas a Retalho)

Países abrangidos

Japão, China, Coreia do Sul, Índia, Austrália, Singapura, Tailândia, Malásia, Indonésia, Filipinas, Vietname, Resto da Ásia-Pacífico

Participantes do mercado abrangidos

Canon Inc., FUJIFILM Holdings Corporation, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, Illumina, Koninklijke Philips NV, Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Abbott, General Electric Company, BD, QIAGEN, DIASORIN SPA, Merck KGaA, Hologic, Myriad Genetics Inc., BIOMERIEUX, FONAR Corp., Time Medical Holding., PlexBio., MinFound Medical Systems Co., Ltd, Medonica Co. LTD, Beijing O&D Biotech Co., Ltd., e SternMed GmbH. entre outros.

Definição de mercado

O cancro da tiroide é um tipo de cancro que começa na glândula tiroideia. O cancro começa quando as células começam a crescer descontroladamente. A glândula tiróide produz hormonas que ajudam a regular o metabolismo, a frequência cardíaca, a pressão arterial e a temperatura corporal. A glândula tiróide está na parte anterior do pescoço, abaixo da cartilagem tiróide (pomo de Adão). Na maioria das pessoas, a tiroide não pode ser vista nem sentida. Tem a forma de uma borboleta, com dois lóbulos – o lobo direito e o lobo esquerdo – unidos por um pedaço estreito da glândula chamado istmo.

Dinâmica do mercado de diagnóstico de cancro da tiroide Ásia-Pacífico

MOTORISTAS

AUMENTO DA INCIDÊNCIA E PREVALÊNCIA DE NÓDULOS DA TIROIDE E CANCRO

Um nódulo da tiroide é um crescimento (nódulo) invulgar de células da tiroide na glândula tiroideia. Por vezes, o tecido mole normal da tiroide começou a crescer, provocando a formação destes nódulos. A incidência de nódulos aumenta com a idade e principalmente nas mulheres, principalmente naquelas com deficiência de iodo e após exposição à radiação. Embora a complicação adicional destes nódulos seja o cancro da tiroide, as hipóteses de conversão de nódulos da tiroide em cancro da tiroide são baixas. De acordo com um artigo publicado no NCBI denominado "Risco de malignidade em nódulos da tiroide de 4 cm ou maiores" em 2017, a ocorrência de cancro após nódulos é encontrada em menos de 5% do total de casos de nódulos. Além disso, os nódulos da tiroide ocorrem na história familiar e em pessoas cuja ingestão de iodo é baixa.

TESTES DE DIAGNÓSTICO DE CANCRO DA TIROIDE AUMENTANDO

A ecografia da tiroide é uma imagem de ondas sonoras da glândula tiroide obtida por um instrumento portátil e traduzida numa imagem bidimensional num monitor. É utilizado no diagnóstico de tumores, quistos ou bócios da tiroide e é um procedimento indolor e sem riscos. Estes testes são utilizados para avaliar anomalias estruturais, enquanto os exames sanguíneos que medem os níveis de TSH, T4 e T3 são utilizados para examinar variáveis ​​funcionais. A biópsia por agulha fina é utilizada em casos suspeitos para determinar se um tumor é benigno ou maligno. Além disso, a introdução de testes moleculares e o prognóstico genético alimentam o panorama diagnóstico neste mercado de diagnóstico do cancro da tiroide.

AUMENTAR A CONSCIÊNCIA SOBRE O CANCRO DA TIROIDE

A crescente consciencialização sobre o cancro da tiroide levou a um aumento da procura pela deteção atempada do cancro, levando ao crescimento do mercado.

O cancro da tiroide é uma das principais causas do aumento das taxas de mortalidade entre as populações dos EUA em todo o mundo, alimentando o crescimento do mercado nos próximos cinco anos. A exposição à radiação e um historial familiar de problemas da tiroide são os principais fatores de risco para o cancro da tiroide. As mulheres são diagnosticadas com cancro da tiroide significativamente mais do que os homens.

RESTRIÇÕES

ALTO CUSTO DO PROCEDIMENTO DE DIAGNÓSTICO

Os diagnósticos de cancro tornaram-se cada vez mais dispendiosos devido ao número crescente de doentes com cancro da tiroide e ao aumento dos preços dos dispositivos médicos. Os modernos dispositivos tecnológicos utilizados no diagnóstico do cancro desempenham também um papel significativo nos elevados preços do diagnóstico do cancro e na elevada precisão no fornecimento de um diagnóstico definitivo do cancro nos nódulos da tiróide. Portanto, o elevado custo dos procedimentos de diagnóstico para o cancro da tiroide está a dificultar o crescimento do mercado.

Os produtos ou dispositivos de diagnóstico utilizados na deteção do cancro estão a tornar-se avançados, mas, juntamente com isto, os procedimentos para o diagnóstico do cancro também são dispendiosos, o que dificulta o crescimento do mercado de diagnóstico do cancro da tiroide porque os dispositivos são utilizados no processo de cancro o diagnóstico torna-se mais dispendioso, o que resulta no aumento do custo do procedimento de diagnóstico. Assim, o elevado custo dos diagnósticos de cancro atua como uma restrição para o mercado de diagnóstico de cancro da tiroide da Ásia-Pacífico.

DANOS TECIDOS DEVIDO À ELEVADA EXPOSIÇÃO À RADIAÇÃO DOS TESTES DE IMAGEM

A elevada exposição à radiação causa danos significativos nos tecidos e aumenta a probabilidade de uma pessoa adquirir cancro posteriormente. Embora seja vital manter este risco no contexto, as pequenas doses de radiação utilizadas para exames de imagem podem aumentar marginalmente o risco de uma pessoa desenvolver cancro. A quantidade de radiação que uma pessoa recebe varia de acordo com o tipo de teste, a área do corpo exposta, o tamanho do corpo, a idade e o sexo, entre outras coisas. Os exames de imagem que empregam radiação só devem ser realizados quando necessário, porque a exposição à radiação de todas as fontes pode aumentar ao longo da vida e aumentar a probabilidade de desenvolver cancro. Outros procedimentos de imagem, como a ecografia ou a ressonância magnética, também podem ser utilizados com frequência.

OPORTUNIDADES

AUMENTO DAS DESPESAS DE SAÚDE PARA DIAGNÓSTICO E TRATAMENTO DO CANCRO

Em todo o mundo, as actividades de I&D estão a aumentar devido às despesas de saúde pública com desempenhos económicos, ao passo que o sector dos cuidados de saúde ocupa o segundo lugar entre todos os sectores no que diz respeito ao montante gasto em cuidados de saúde . O aumento das despesas com cuidados de saúde pode resultar numa melhor oferta de oportunidades de I&D. Prevê-se que aumente a procura por diagnósticos de cancro do ovário.

O aumento dos gastos com os cuidados de saúde para o tratamento do cancro também ajuda os doentes a realizar diagnósticos e tratamentos avançados sem complicações para uma recuperação rápida. As despesas com cuidados de saúde são compostas por pagamentos diretos (pessoas que pagam os seus próprios cuidados), despesas governamentais e fontes, incluindo seguros de saúde e atividades de Organizações Não Governamentais (ONG). Devido a este aumento dos gastos com saúde para tratamento do cancro , funciona como uma oportunidade de crescimento do mercado.

DESAFIOS

QUADRO REGULATÓRIO RIGOROSO PARA A APROVAÇÃO E COMERCIALIZAÇÃO DE PRODUTOS PARA O DIAGNÓSTICO DO CANCRO

As rigorosas regulamentações para a aprovação e comercialização de qualquer produto no mercado estão a revelar-se um dos principais desafios para os fabricantes de produtos de diagnóstico do cancro nos EUA e na região europeia. Cada país tem regulamentos e um organismo diferente para os procedimentos regulamentares.

As possíveis vias regulamentares são obrigatórias para a libertação, aprovação ou aceitação de assinaturas complexas pela Food and Drug Administration (FDA) dos EUA. As vias regulamentares incluem regulamentos aplicáveis ​​aos dispositivos de diagnóstico in vitro (IVD), incluindo dispositivos de diagnóstico complementares, o potencial de marcação como diagnóstico complementar e o programa de qualificação de biomarcadores.

Desenvolvimentos recentes

  • Em agosto de 2022, a F. Hoffmann-La Roche Ltd anunciou o lançamento do Digital LightCycler System, o primeiro sistema digital de reação em cadeia da polimerase (PCR) da Roche. Este sistema de última geração deteta doenças e foi concebido para quantificar com precisão vestígios de alvos específicos de ADN e ARN que normalmente não são detetáveis ​​pelos métodos convencionais de PCR. Isto ajudou a empresa a aumentar a sua presença no mercado da Ásia-Pacífico
  • Em maio de 2022, a Thermo Fisher Scientific Inc., líder mundial no serviço à ciência, lançou o Microscópio Eletrónico de Transmissão Cryo Glacios 2 da Thermo Scientific (Cryo-TEM), um microscópio potente com nova automatização e capacidades de imagem de alta resolução concebidos para ajudar a crio Investigadores de microscopia eletrónica (crio-EM) com vários níveis de experiência aceleram a descoberta de medicamentos baseados na estrutura. Este método avançado, rápido e económico para a concepção de medicamentos pode permitir aos clientes acelerar o ritmo da investigação de doenças debilitantes como as doenças de Alzheimer, Parkinson e Huntington, bem como a investigação do cancro e de mutações genéticas.

Âmbito do mercado de diagnóstico de cancro da tiroide Ásia-Pacífico

O mercado de diagnóstico do cancro da tiroide Ásia-Pacífico está segmentado em tipo de produto, tipo de teste, tipo de cancro, fases, faixa etária, utilizador final e canal de distribuição. O crescimento entre estes segmentos irá ajudá-lo a analisar os escassos segmentos de crescimento nas indústrias e a fornecer aos utilizadores uma valiosa visão geral do mercado e insights de mercado para tomar decisões estratégicas para identificar as principais aplicações do mercado.

Tipo de produto

  • Instrumentos
  • Consumíveis e acessórios

Com base no tipo de produto, o mercado de diagnóstico do cancro da tiroide da Ásia-Pacífico está segmentado em instrumentos e consumíveis e acessórios.

Tipo de teste

  • Teste de imagem
  • Exame de sangue
  • Biópsia
  • Outros

Com base no tipo de teste, o mercado de diagnóstico do cancro da tiroide da Ásia-Pacífico está segmentado em exames de imagem, análises ao sangue, biópsias e outros.

Tipo de cancro

  • Carcinoma Papilar
  • Carcinoma Folicular
  • Outros

Com base no tipo de cancro, o mercado de diagnóstico do cancro da tiroide da Ásia-Pacífico está segmentado em carcinoma papilar, carcinoma folicular, entre outros.

Estágios

  • Estágio I
  • Estágio II
  • Estágio III
  • Estágio IV

Com base nos estádios, o mercado de diagnóstico do cancro da tiroide da Ásia-Pacífico está segmentado no estádio I, estádio II, estádio III e estádio IV.

Age Group

  • 30-65
  • 65 and above
  • 21-29
  • Below 21

On the basis of age group, the Asia-Pacific thyroid cancer diagnostics market is segmented into 30-65, 65 and above, 21-29, and below 21.

End User

  • Hospitals
  • Associated Labs
  • Independent Diagnostic Laboratories
  • Diagnostic Imaging Centers
  • Cancer Research Institutes
  • Others

On the basis of end user, the Asia-Pacific thyroid cancer diagnostics market is segmented into hospitals, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.

Distribution Channel

  • Direct Tender
  • Retail Sales

On the basis of distribution channel, the Asia-Pacific thyroid cancer diagnostics market is segmented into direct tender and retail sales.

Mercado de diagnóstico de cancro da tiroide

Asia-Pacific Thyroid Cancer Diagnostics Market Regional Analysis/Insights  

The Asia-Pacific thyroid cancer diagnostics market is analysed, and market size insights and trends are provided by country, product type, test type, cancer type, stages, age group, end user, and distribution channel, as referenced above.

The countries covered in this market report are Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and the Rest of Asia-Pacific

China is expected to dominate the Asia-Pacific thyroid cancer diagnostics market in terms of market share and revenue and will continue to dominate during the forecast period. This is due to a rising preference for preventive health check-ups.

The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Asia-Pacific brands and their challenges faced due to competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Asia-Pacific Thyroid Cancer Diagnostics Market Share Analysis

Asia-Pacific thyroid cancer diagnostics market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the Asia-Pacific thyroid cancer diagnostics market.

Alguns dos principais players que operam no mercado de diagnóstico do cancro da tiroide Ásia-Pacífico são a Canon Inc., a FUJIFILM Holdings Corporation, a F. Hoffmann-La Roche Ltd, a Quest Diagnostics Incorporated, a Illumina, a Koninklijke Philips NV, a Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Abbott, General Electric Company, BD, QIAGEN, DIASORIN SPA, Merck KGaA, Hologic, Myriad Genetics Inc., BIOMERIEUX, FONAR Corp., Time Medical Holding., PlexBio., MinFound Medical Systems Co., Ltd, Medonica Co. LTD, Beijing O&D Biotech Co., Ltd. e SternMed GmbH. entre outros.


SKU-

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

  • Painel interativo de análise de dados
  • Painel de análise da empresa para oportunidades de elevado potencial de crescimento
  • Acesso de analista de pesquisa para personalização e customização. consultas
  • Análise da concorrência com painel interativo
  • Últimas notícias, atualizações e atualizações Análise de tendências
  • Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET TESTING TYPE COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS

5 EPIDEMIOLOGY

6 REGULATORY FRAMEWORK OF THE ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET

6.1 REGULATORY SCENARIO IN THE U.S.

6.2 REGULATORY SCENARIO IN AUSTRALIA

6.3 REGULATORY SCENARIO IN JAPAN

6.4 REGULATORY SCENARIO IN CHINA

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISING INCIDENCE AND PREVALENCE OF THYROID NODULES AND CANCER

7.1.2 RISING THYROID CANCER DIAGNOSTIC TESTS

7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS

7.1.4 RISING AWARENESS TOWARDS THYROID CANCER

7.2 RESTRAINTS

7.2.1 HIGH COST OF DIAGNOSTICS PROCEDURE

7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS

7.3 OPPORTUNITIES

7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT

7.3.2 RISING OBESE POPULATION

7.4 CHALLENGES

7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS

7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE

8 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE

8.1 OVERVIEW

8.2 INSTRUMENTS

8.2.1 PATHOLOGY BASED INSTRUMENTS

8.2.1.1 PCR INSTRUMENTS

8.2.1.2 SLIDE STAINING SYSTEMS

8.2.1.3 TISSUE PROCESSING SYSTEMS

8.2.1.4 CELL PROCESSORS

8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS

8.2.2 IMAGING INSTRUMENTS

8.2.2.1 ULTRASOUND SYSTEMS

8.2.2.2 CT SYSTEMS

8.2.2.3 MRI SYSTEMS

8.2.2.4 OTHERS

8.2.3 BIOPSY INSTRUMENTS

8.2.3.1 NEEDLE BIOPSY

8.2.3.2 ENDOSCOPIC BIOPSY

8.2.3.3 CORE BIOPSY

8.2.3.4 OTHERS

8.2.4 OTHERS

8.3 CONSUMABLES & ACCESSORIES

8.3.1 KITS

8.3.1.1 PCR KITS

8.3.1.2 DNA POLYMERASE KITS

8.3.1.3 NUCLEIC ACID ISOLATION KITS

8.3.1.4 OTHERS

8.3.2 REAGENTS

8.3.2.1 ASSAYS

8.3.2.2 BUFFERS

8.3.2.3 PRIMERS

8.3.2.4 OTHERS

8.3.3 PROBES

8.3.4 OTHER CONSUMABLES

9 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE

9.1 OVERVIEW

9.2 IMAGING TEST

9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN

9.2.2 MRI

9.2.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN

9.2.4 OTHERS

9.3 BLOOD TEST

9.3.1 BLOOD CHEMISTRY TESTS

9.3.2 COMPLETE BLOOD COUNT (CBC)

9.3.3 OTHERS

9.4 BIOPSY

9.4.1 NEEDLE BIOPSY

9.4.2 BRONCHOSCOPY BIOPSY

9.4.3 CORE BIOPSY

9.4.4 OTHERS

9.5 OTHERS

10 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE

10.1 OVERVIEW

10.2 PAPILLARY CARCINOMA

10.3 FOLLICULAR CARCINOMA

10.4 OTHERS

11 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY STAGES

11.1 OVERVIEW

11.2 STAGE I

11.3 STAGE II

11.4 STAGE III

11.5 STAGE IV

12 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP

12.1 OVERVIEW

12.2 30-65

12.3 65 AND ABOVE

12.4 21-29

12.5 BELOW 21

13 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITALS

13.3 ASSOCIATED LABS

13.4 INDEPENDENT DIAGNOSTIC LABORATORIES

13.5 DIAGNOSTIC IMAGING CENTERS

13.6 CANCER RESEARCH INSTITUTES

13.7 OTHERS

14 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 DIRECT TENDER

14.3 RETAIL SALES

15 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY REGION

15.1 ASIA-PACIFIC

15.1.1 JAPAN

15.1.2 CHINA

15.1.3 SOUTH KOREA

15.1.4 INDIA

15.1.5 THAILAND

15.1.6 SINGAPORE

15.1.7 INDONESIA

15.1.8 MALAYSIA

15.1.9 PHILIPPINES

15.1.10 AUSTRALIA

15.1.11 VIETNAM

15.1.12 REST OF ASIA-PACIFIC

16 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 CANON INC.

18.1.1 COMPANY SNAPSHOT

18.1.2 COMPANY SHARE ANALYSIS

18.1.3 PRODUCT PORTFOLIO

18.1.4 RECENT DEVELOPMENTS

18.2 FUJIFILM CORPORATION

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENT

18.3 F. HOFFMANN-LA ROCHE LTD

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 QUEST DIAGNOSTICS INCORPORATED

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENTS

18.5 ILLUMINA, INC.

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENT

18.6 ABBOTT

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENT

18.7 BD

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENT

18.8 BEIJING O&D BIOTECH CO., LTD.

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENTS

18.9 BIOMÉRIEUX SA

18.9.1 COMPANY SNAPSHOT

18.9.2 REVENUE ANALYSIS

18.9.3 PRODUCT PORTFOLIO

18.9.4 RECENT DEVELOPMENTS

18.1 DIASORIN S.P.A.

18.10.1 COMPANY SNAPSHOT

18.10.2 REVENUE ANALYSIS

18.10.3 PRODUCT PORTFOLIO

18.10.4 RECENT DEVELOPMENT

18.11 FONAR CORP.

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENTS

18.12 GENERAL ELECTRIC

18.12.1 COMPANY SNAPSHOT

18.12.2 REVENUE ANALYSIS

18.12.3 PRODUCT PORTFOLIO

18.12.4 RECENT DEVELOPMENTS

18.13 HOLOGIC INC.

18.13.1 COMPANY SNAPSHOT

18.13.2 REVENUE ANALYSIS

18.13.3 PRODUCT PORTFOLIO

18.13.4 RECENT DEVELOPMENT

18.14 KONINKLIJKE PHILIPS N.V.

18.14.1 COMPANY SNAPSHOT

18.14.2 REVENUE ANALYSIS

18.14.3 PRODUCT PORTFOLIO

18.14.4 RECENT DEVELOPMENT

18.15 MERCK KGAA.

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENT

18.16 MEDONICA CO. LTD

18.16.1 COMPANY SNAPSHOT

18.16.2 PRODUCT PORTFOLIO

18.16.3 RECENT DEVELOPMENT

18.17 MINFOUND MEDICAL SYSTEMS CO. LTD

18.17.1 COMPANY SNAPSHOT

18.17.2 PRODUCT PORTFOLIO

18.17.3 RECENT DEVELOPMENTS

18.18 MYRIAD GENETICS, INC.

18.18.1 COMPANY SNAPSHOT

18.18.2 REVENUE ANALYSIS

18.18.3 PRODUCT PORTFOLIO

18.18.4 RECENT DEVELOPMENTS

18.19 PLEXBIO.

18.19.1 COMPANY SNAPSHOT

18.19.2 PRODUCT PORTFOLIO

18.19.3 RECENT DEVELOPMENTS

18.2 QIAGEN

18.20.1 COMPANY SNAPSHOT

18.20.2 REVENUE ANALYSIS

18.20.3 PRODUCT PORTFOLIO

18.20.4 RECENT DEVELOPMENT

18.21 STERNMED GMBH

18.21.1 COMPANY SNAPSHOT

18.21.2 PRODUCT PORTFOLIO

18.21.3 RECENT DEVELOPMENTS

18.22 SIEMENS HEALTHCARE GMBH

18.22.1 COMPANY SNAPSHOT

18.22.2 REVENUE ANALYSIS

18.22.3 PRODUCT PORTFOLIO

18.22.4 RECENT DEVELOPMENT

18.23 TIME MEDICAL HOLDING.

18.23.1 COMPANY SNAPSHOT

18.23.2 PRODUCT PORTFOLIO

18.23.3 RECENT DEVELOPMENT

18.24 THERMO FISHER SCIENTIFIC INC.

18.24.1 COMPANY SNAPSHOT

18.24.2 REVENUE ANALYSIS

18.24.3 PRODUCT PORTFOLIO

18.24.4 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

Lista de Tabela

TABLE 1 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 2 ASIA PACIFIC INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 ASIA PACIFIC INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 4 ASIA PACIFIC PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 5 ASIA PACIFIC IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 6 ASIA PACIFIC BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 7 ASIA PACIFIC CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 ASIA PACIFIC CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 9 ASIA PACIFIC KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 10 ASIA PACIFIC REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 11 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 12 ASIA PACIFIC IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 ASIA PACIFIC IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 14 ASIA PACIFIC BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 ASIA PACIFIC BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 16 ASIA PACIFIC BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 ASIA PACIFIC BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 18 ASIA PACIFIC OTHERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 20 ASIA PACIFIC PAPILLARY CARCINOMA IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 ASIA PACIFIC FOLLICULAR CARCINOMA IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 ASIA PACIFIC OTHERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 24 ASIA PACIFIC STAGE I IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 ASIA PACIFIC STAGE II IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 ASIA PACIFIC STAGE III IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 ASIA PACIFIC STAGE IV IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 29 ASIA PACIFIC 30-65 IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 ASIA PACIFIC 65 AND ABOVE IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 ASIA PACIFIC 21-29 IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 ASIA PACIFIC BELOW 21 IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 34 ASIA PACIFIC HOSPITALS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 ASIA PACIFIC ASSOCIATED LABS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 36 ASIA PACIFIC INDEPENDENT DIAGNOSTIC LABORATORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 ASIA PACIFIC DIAGNOSTIC IMAGING CENTERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 38 ASIA PACIFIC CANCER RESEARCH INSTITUTES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 ASIA PACIFIC OTHERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 41 ASIA PACIFIC DIRECT TENDER IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 ASIA PACIFIC RETAIL SALES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 44 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 45 ASIA-PACIFIC INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 46 ASIA-PACIFIC PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 47 ASIA-PACIFIC IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 48 ASIA-PACIFIC BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 49 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 50 ASIA-PACIFIC KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 51 ASIA-PACIFIC REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 52 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 53 ASIA-PACIFIC IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 54 ASIA-PACIFIC BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 55 ASIA-PACIFIC BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 56 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 57 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 58 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 59 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 60 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 61 JAPAN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 62 JAPAN INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 63 JAPAN PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 64 JAPAN IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 65 JAPAN BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 66 JAPAN CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 67 JAPAN KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 68 JAPAN REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 69 JAPAN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 70 JAPAN IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 71 JAPAN BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 72 JAPAN BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 73 JAPAN THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 74 JAPAN THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 75 JAPAN THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 76 JAPAN THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 77 JAPAN THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 78 CHINA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 79 CHINA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 80 CHINA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 81 CHINA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 82 CHINA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 83 CHINA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 84 CHINA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 85 CHINA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 86 CHINA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 87 CHINA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 88 CHINA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 89 CHINA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 90 CHINA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 91 CHINA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 92 CHINA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 93 CHINA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 94 CHINA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 95 SOUTH KOREA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 96 SOUTH KOREA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 97 SOUTH KOREA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 98 SOUTH KOREA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 99 SOUTH KOREA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 100 SOUTH KOREA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 101 SOUTH KOREA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 102 SOUTH KOREA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 103 SOUTH KOREA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 104 SOUTH KOREA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 105 SOUTH KOREA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 106 SOUTH KOREA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 107 SOUTH KOREA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 108 SOUTH KOREA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 109 SOUTH KOREA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 110 SOUTH KOREA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 111 SOUTH KOREA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 112 INDIA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 113 INDIA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 114 INDIA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 115 INDIA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 116 INDIA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 117 INDIA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 118 INDIA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 119 INDIA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 120 INDIA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 121 INDIA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 122 INDIA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 123 INDIA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 124 INDIA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 125 INDIA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 126 INDIA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 127 INDIA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 128 INDIA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 129 THAILAND THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 130 THAILAND INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 131 THAILAND PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 132 THAILAND IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 133 THAILAND BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 134 THAILAND CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 135 THAILAND KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 136 THAILAND REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 137 THAILAND THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 138 THAILAND IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 139 THAILAND BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 140 THAILAND BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 141 THAILAND THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 142 THAILAND THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 143 THAILAND THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 144 THAILAND THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 145 THAILAND THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 146 SINGAPORE THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 147 SINGAPORE INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 148 SINGAPORE PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 149 SINGAPORE IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 150 SINGAPORE BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 151 SINGAPORE CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 152 SINGAPORE KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 153 SINGAPORE REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 154 SINGAPORE THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 155 SINGAPORE IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 156 SINGAPORE BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 157 SINGAPORE BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 158 SINGAPORE THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 159 SINGAPORE THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 160 SINGAPORE THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 161 SINGAPORE THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 162 SINGAPORE THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 163 INDONESIA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 164 INDONESIA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 165 INDONESIA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 166 INDONESIA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 167 INDONESIA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 168 INDONESIA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 169 INDONESIA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 170 INDONESIA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 171 INDONESIA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 172 INDONESIA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 173 INDONESIA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 174 INDONESIA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 175 INDONESIA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 176 INDONESIA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 177 INDONESIA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 178 INDONESIA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 179 INDONESIA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 180 MALAYSIA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 181 MALAYSIA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 182 MALAYSIA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 183 MALAYSIA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 184 MALAYSIA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 185 MALAYSIA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 186 MALAYSIA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 187 MALAYSIA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 188 MALAYSIA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 189 MALAYSIA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 190 MALAYSIA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 191 MALAYSIA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 192 MALAYSIA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 193 MALAYSIA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 194 MALAYSIA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 195 MALAYSIA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 196 MALAYSIA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 197 PHILIPPINES THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 198 PHILIPPINES INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 199 PHILIPPINES PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 200 PHILIPPINES IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 201 PHILIPPINES BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 202 PHILIPPINES CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 203 PHILIPPINES KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 204 PHILIPPINES REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 205 PHILIPPINES THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 206 PHILIPPINES IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 207 PHILIPPINES BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 208 PHILIPPINES BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 209 PHILIPPINES THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 210 PHILIPPINES THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 211 PHILIPPINES THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 212 PHILIPPINES THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 213 PHILIPPINES THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 214 AUSTRALIA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 215 AUSTRALIA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 216 AUSTRALIA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 217 AUSTRALIA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 218 AUSTRALIA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 219 AUSTRALIA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 220 AUSTRALIA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 221 AUSTRALIA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 222 AUSTRALIA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 223 AUSTRALIA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 224 AUSTRALIA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 225 AUSTRALIA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 226 AUSTRALIA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 227 AUSTRALIA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 228 AUSTRALIA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 229 AUSTRALIA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 230 AUSTRALIA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 231 VIETNAM THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 232 VIETNAM INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 233 VIETNAM PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 234 VIETNAM IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 235 VIETNAM BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 236 VIETNAM CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 237 VIETNAM KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 238 VIETNAM REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 239 VIETNAM THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 240 VIETNAM IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 241 VIETNAM BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 242 VIETNAM BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 243 VIETNAM THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 244 VIETNAM THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 245 VIETNAM THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 246 VIETNAM THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 247 VIETNAM THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 248 REST OF ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

Lista de Figura

FIGURE 1 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: MARKET TESTING TYPE COVERAGE GRID

FIGURE 9 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT THYROID CANCER IS EXPECTED TO DRIVE THE ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD

FIGURE 12 PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET

FIGURE 14 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022

FIGURE 15 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)

FIGURE 16 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)

FIGURE 17 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 18 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022

FIGURE 19 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)

FIGURE 20 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)

FIGURE 21 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 22 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022

FIGURE 23 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)

FIGURE 24 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)

FIGURE 25 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE

FIGURE 26 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, 2022

FIGURE 27 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, 2023-2030 (USD MILLION)

FIGURE 28 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, CAGR (2023-2030)

FIGURE 29 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, LIFELINE CURVE

FIGURE 30 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022

FIGURE 31 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)

FIGURE 32 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)

FIGURE 33 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 34 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY END USER, 2022

FIGURE 35 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 36 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 37 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 39 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 40 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 41 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 42 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 43 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 44 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 45 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 46 ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030)

FIGURE 47 ASIA PACIFIC THYROID CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

View Detailed Information Right Arrow

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados ​​e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis ​​de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

The Asia-Pacific thyroid cancer diagnostics market size will be worth USD 1,572.00 million by 2030.
The growth rate of the Asia-Pacific thyroid cancer diagnostics market is 5.0% in the forecast period by 2030.
Rising incidence and prevalence of thyroid nodules & cancer & rising thyroid cancer diagnostic tests are the growth drivers of the Asia-Pacific thyroid cancer diagnostics market.
Product type, test type, cancer type, stages, age group, end user, and distribution channel are the factors on which the Asia-Pacific thyroid cancer diagnostics market research is based.
Major companies in the Asia-Pacific thyroid cancer diagnostics market are Canon Inc., FUJIFILM Holdings Corporation, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, Illumina, Koninklijke Philips N.V., Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Abbott, General Electric Company, BD, QIAGEN, DIASORIN S.P.A., Merck KGaA, Hologic, Myriad Genetics Inc., BIOMERIEUX, FONAR Corp., Time Medical Holding., PlexBio., MinFound Medical Systems Co., Ltd, Medonica Co. LTD, Beijing O&D Biotech Co., Ltd., and SternMed GmbH. among others.